Evotec has developed substantial expertise in the immunology and inflammation fields and has built through collaborations and partnerships a state-of-the-art integrated drug discovery platform covering all aspects from target identification to investigational new drug (“IND”).
Our experienced immunology & inflammation team with over 30 scientists has an established and proven track record and has contributed to the discovery and development of multiple pre-clinical and clinical candidates in the area of inflammation, autoimmune disorders, pain and endometriosis.
Evotec’s core expertise in small molecule drug discovery in immunology and inflammation is complemented by a growing state-of-the-art know-how in the development of therapeutic antibodies.
Key capabilities of Evotec’s immunology & inflammation discovery platform
- Access complex cellular environments and use of primary cells and tissues
- Assay platform routinely used to support both HTS and H2L/LO programmes for functional read-outs of lymphocytes, monocytes or other target cell types
- Integrated into Evotec’s MS-based proteomic platform to aid target identification